|Conţinutul numărului revistei|
|Ultima descărcare din IBN:|
|Căutarea după subiecte |
similare conform CZU
|Piele. Tegumente în general. Dermatologie clinică. Tulburări cutanate (148)|
| SM ISO690:2012|
MEREUŢĂ, Ion; SCUTARI, Oleg. Aspectele clinico-metodologice ale limfoamelor cutanate T/NK. In: Revista ştiinţifico-practică ”Info-Med” . 2016, nr. 2(28-2), pp. 97-103. ISSN 1810-3936.
|Revista ştiinţifico-practică ”Info-Med”|
|Numărul 2(28-2) / 2016 / ISSN 1810-3936|
Primary cutaneous lymphomas morbidity (PCL) increases with age, reaching the highest level in people aged over 60 years, amid immunosuppression. Malignant lymphomas arise from degeneration of lymphocytes, cells whose key role is immunity. Within the group consisting of PCL, three categories can be distinguished: cutaneous T-cell lymphoma (CTCL) representing 42.6%, cutaneous B-cell lymphoma (CBCL) 32.1% and histiocytic lymphoma - 25.3%. Due to histological variability, cutaneous lymphomas clinically have polymorphic pathological manifestations, such as patches or plaques of different shades, nodule, bubbles, papules, pustules, dyshidrotic rashes, erythroderma etc. There are also some tumor types where lesions may become extensive, aggressive, can affect the lymph nodes and other organs, with a low cure rate. Diagnosis of lymphoma is a very difficult process. This can be done only by combining the clinical, histological, immunophenotypic arguments and genotypic evolution. The treatment depends on the stage of the cutaneous cancer. Thus, in the early stages forefront options include assigning a systemic therapy with interferon alfa or acitretin, retinoids and rexinoids with PUVA therapy, while in advanced stages chemotherapy combination with bexarotene, denileukin difitov, interferon ɑ2a, alemtuzumab or methotrexate in low doses are used. It is very important to create a team of specialists (oncologist, dermatologist, family physician and clinician pharmacist) to conduct effective individualized treatment regimens by monitoring the state of patients with cutaneous lymphomas.
cutaneous lymphomas, individualized treatment,
immunosuppression, lymph nodes